ArticleAnimal genetics2026
ABCB1 Frameshift Deletion in Skye Terriers With Potential Pharmacogenetic Relevance.
Article in Animal genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ivermectin-associated neurotoxicity is a potentially life-threatening condition caused by disruption of the ABCB1 encoded P-glycoprotein drug transporter in certain dog breeds. Skye terriers are considered at increased risk of ivermectin toxicity despite the absence of an identified molecular cause. We searched the Dog10K variant dataset for ABCB1 variants potentially underlying ivermectin sensitivity in Skye terriers and screened an independent cohort of 27 dogs to confirm sequence variants. A 1-bp frameshift deletion predicted to cause loss of function in ABCB1 was identified in two of three Skye terriers in the Dog10K dataset and was absent from all 1869 non-Skye-terrier genomes. The variant had an allele frequency of 16.7% in the independent Skye terrier cohort. This is the first reported ABCB1 variant in Skye terriers and represents a plausible candidate genetic basis for the anecdotally observed ivermectin sensitivity in the breed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.